151 related articles for article (PubMed ID: 38428815)
21. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
22. Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study.
Gallacher D; Kimani P; Stallard N
Med Decis Making; 2021 May; 41(4):476-484. PubMed ID: 33626961
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
Filleron T; Bachelier M; Mazieres J; Pérol M; Meyer N; Martin E; Mathevet F; Dauxois JY; Porcher R; Delord JP
JAMA Netw Open; 2021 Dec; 4(12):e2139573. PubMed ID: 34932105
[TBL] [Abstract][Full Text] [Related]
24. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Gibson E; Koblbauer I; Begum N; Dranitsaris G; Liew D; McEwan P; Tahami Monfared AA; Yuan Y; Juarez-Garcia A; Tyas D; Lees M
Pharmacoeconomics; 2017 Dec; 35(12):1257-1270. PubMed ID: 28866758
[TBL] [Abstract][Full Text] [Related]
25. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
26. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
28. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
[TBL] [Abstract][Full Text] [Related]
29. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
Quinn C; Garrison LP; Pownell AK; Atkins MB; de Pouvourville G; Harrington K; Ascierto PA; McEwan P; Wagner S; Borrill J; Wu E
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661115
[TBL] [Abstract][Full Text] [Related]
30. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS; Burns D; Kiff C; Lee D
Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
[TBL] [Abstract][Full Text] [Related]
31. Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up.
Othus M; Bansal A; Erba H; Ramsey S
Value Health; 2020 Aug; 23(8):1034-1039. PubMed ID: 32828215
[TBL] [Abstract][Full Text] [Related]
32. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
[TBL] [Abstract][Full Text] [Related]
33. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Value Health; 2021 Nov; 24(11):1634-1642. PubMed ID: 34711364
[TBL] [Abstract][Full Text] [Related]
34. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
Cavillon A; Pouessel D; Houédé N; Mathevet F; Dauxois JY; Chevreau C; Culine S; Delord JP; Porcher R; Filleron T
Eur Urol; 2024 Mar; 85(3):293-300. PubMed ID: 36849297
[TBL] [Abstract][Full Text] [Related]
35. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
Che Z; Green N; Baio G
Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
[TBL] [Abstract][Full Text] [Related]
36. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Bullement A; Latimer NR; Bell Gorrod H
Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
[TBL] [Abstract][Full Text] [Related]
37. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
38. An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.
Vickers A
Med Decis Making; 2019 Nov; 39(8):926-938. PubMed ID: 31631772
[No Abstract] [Full Text] [Related]
39. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
van Oostrum I; Ouwens M; Remiro-Azócar A; Baio G; Postma MJ; Buskens E; Heeg B
Value Health; 2021 Sep; 24(9):1294-1301. PubMed ID: 34452709
[TBL] [Abstract][Full Text] [Related]
40. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]